경카테터 심장판막 시장 규모, 점유율, 동향 분석 리포트 : 용도별, 기술별, 지역별, 부문별 예측(2025-2033년)

Transcatheter Heart Valve Market Size, Share & Trends Analysis Report By Application, By Technology, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,728,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,195,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,129,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

경카테터 심장판막 시장 요약

세계의 경카테터 심장판막 시장 규모는 2024년에 54억 9,000만 달러로 추정되며, 2033년까지 212억 4,000만 달러에 달할 것으로 예측됩니다.

2025-2033년 연평균 16.49%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 특히 고령화 사회에서 심장판막증 유병률이 증가하면서 대동맥판막협착증, 승모판막역류증 등의 질환에 대한 TAVR(경피적 대동맥판막치환술)을 비롯한 경피적 심장판막(THV) 치료 수요를 견인하고 있습니다.

경카테터 심장판막 산업의 성장을 이끄는 주요 요인으로는 지속적인 THV 설계 개선, 영상 진단 기술 및 전달 시스템의 발전, 그리고 기존 개흉 수술에 비해 회복 기간 단축, 합병증 감소, 의료비 절감 효과가 기대되는 최소 침습적 수술에 대한 선호도 증가 등이 있습니다.

2024년 9월, 미국 질병예방통제센터(CDC)는 미국 성인의 75%가 심장판막증에 대한 지식이 부족하다고 보고했습니다. 이러한 인식 부족은 특히 65세 이상 노인을 비롯한 고위험군까지 확대되고 있습니다. 미국에서는 매년 500만 명 이상이 심장판막증 진단을 받고 있으며, 이 질환으로 인한 사망자 수는 연간 25,000명 이상에 달할 전망입니다.

특히 고령화 사회에서 심장판막증 유병률이 증가하면서 경피적 심장판막치환술(THV) 수요가 크게 증가하고 있습니다. 대동맥판막협착증, 승모판막역류증과 같은 질환이 보편화됨에 따라 THV와 같은 첨단 치료 솔루션이 요구되고 있습니다. 2024년 9월, CDC는 미국 성인의 75%가 심장판막증에 대한 지식이 제한적이라고 보고했습니다. 이러한 인식 부족은 특히 65세 이상 고령자 등 고위험군까지 확대되고 있습니다. 미국에서는 매년 500만 명 이상이 심장판막증 진단을 받고 있으며, 이 질환으로 인한 사망자 수는 연간 25,000명 이상에 달할 전망입니다.

THV 설계의 지속적인 개선, 특히 밸브의 내구성 향상, 이식 용이성, 환자 결과 개선 등이 중요한 촉진요인입니다. 영상 진단 기술의 발전과 판막 전달 시스템의 개선도 시술 성공률을 크게 향상시켜 THV 시술의 대상 환자층을 확대했습니다. 2024년 8월, 보스턴 사이언티픽은 ACURATE Prime 대동맥 판막 시스템이 CE 마크 인증을 획득했다고 발표했습니다. 이 최첨단 경카테터 대동맥판 치환술 시스템은 더 큰 체격의 환자를 위한 새로운 판막 크기를 특징으로 하며, 중증 대동맥판막 협착증을 앓고 있는 저위험, 중위험, 고위험 환자를 대상으로 합니다. 자가 확장형 설계와 개선된 전개 메커니즘을 갖추고 있으며, 밸브의 위치 결정 정확도를 높여 환자의 전반적인 치료 결과를 향상시키고 있습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 경카테터 심장판막 시장 변수, 동향 및 범위

• 시장 계보 전망
  • 모시장 전망
  • 관련·보조 시장 전망
• 시장 역학
• 경카테터 심장판막 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석

제4장 경카테터 심장판막 시장 : 용도별 추정·동향 분석

• 정의와 범위
• 용도별 시장 점유율 분석(2024년 및 2033년)
• 경카테터 대동맥판
• 경카테터 폐동맥판
• 경카테터 승모판

제5장 경카테터 심장판막 시장 : 기술별 추정·동향 분석

• 정의와 범위
• 용도별 시장 점유율 분석(2024년 및 2033년)
• 풍선 확장형 경카테터 판막
• 자기 확장형 경카테터 판막

제6장 경카테터 심장판막 시장 : 지역별 추정·동향 분석

• 지역별 대시보드
• 시장 규모 및 예측, 동향 분석(2021-2033년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 기업/경쟁 분류
• 벤더 구도
  • 주요 기업의 시장 점유율 분석, 2024년
  • Medtronic
  • Abbott
  • Braile Biomedica
  • Meril Life Sciences Pvt. Ltd., Inc.
  • Edwards Lifesciences Corporation
  • MicroPort Scientific Corporation
  • Venus Medtech(Hangzhou) Inc.
  • JenaValve
  • Biosensors International Group, Ltd
  • HLT Medical(Bracco)

KSA

영문 목차

영문목차

Transcatheter Heart Valve Market Summary

The global transcatheter heart valve market size was estimated at USD 5.49 billion in 2024 and projected to reach USD 21.24 billion by 2033, growing at a CAGR of 16.49% from 2025 to 2033. The rising prevalence of heart valve diseases, particularly in the aging population, is driving the demand for transcatheter heart valve (THV) procedures, such as TAVR, especially for conditions such as aortic stenosis and mitral regurgitation.

Key factors propelling the growth of the transcatheter heart valve industry include continuous improvements in THV design, advancements in imaging and delivery systems, and the increasing preference for minimally invasive surgeries, which offer shorter recovery times, reduced complications, and lower healthcare costs compared to traditional open-heart surgery.

In September 2024, the CDC reported that 75% of adults in the U.S. have limited knowledge about heart valve disease. This lack of awareness extends to high-risk groups, particularly individuals aged 65 and older. Each year, over 5 million people in the U.S. receive a diagnosis of heart valve disease, contributing to more than 25,000 fatalities attributed to this condition annually.

The growing prevalence of heart valve diseases, particularly in the aging population, significantly drives the demand for transcatheter heart valve (THV) procedures. Conditions such as aortic stenosis and mitral regurgitation are becoming more common, necessitating advanced treatment solutions such as THVs. In September 2024, the CDC reported that 75% of adults in the U.S. have limited knowledge about heart valve disease. This lack of awareness extends to high-risk groups, particularly individuals aged 65 and older. Each year, over 5 million people in the U.S. receive a diagnosis of heart valve disease, contributing to more than 25,000 fatalities attributed to this condition annually.

Continuous improvements in THV design, including enhanced valve durability, ease of implantation, and improved patient outcomes, are crucial drivers. Advancements in imaging techniques and valve delivery systems have also significantly improved procedural success and expanded the patient pool eligible for THV procedures. In August 2024, Boston Scientific announced that its ACURATE Prime Aortic Valve System has received CE mark approval. This state-of-the-art transcatheter aortic valve replacement system features a new valve size to serve patients with larger anatomies and is indicated for individuals at low, intermediate, and high risk experiencing severe aortic stenosis. The system features a self-expanding design and a refined deployment mechanism, enhancing the accuracy of valve positioning to improve overall patient outcomes.

Global Transcatheter Heart Valve Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global transcatheter heart valve market report based on application, technology, and region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Transcatheter Aortic Valve
• Transcatheter Pulmonary Valve
• Transcatheter Mitral Valve
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Balloon Expanded Transcatheter Valve
• Self-Expanded Transcatheter Valve
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Technology
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Transcatheter Heart Valve Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of valvular heart diseases and aging population
    • 3.2.1.2. Increasing preference for minimally invasive cardiac procedures
    • 3.2.1.3. Technological advancements in valve design and delivery systems
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High procedural and device costs limiting accessibility
    • 3.2.2.2. Complications related to valve durability and thrombosis risk
  • 3.2.3. Market developments
    • 3.2.3.1. Key clinical trials in the transcatheter heart valve market, by region
    • 3.2.3.2. Recent product launches in the transcatheter heart valve market, by region
    • 3.2.3.3. Emerging products in the transcatheter heart valve market, by region
  • 3.2.4. Competitive factors and strategies
    • 3.2.4.1. Clinical insights
    • 3.2.4.2. Emerging technologies
    • 3.2.4.3. Market appeal
    • 3.2.4.4. Physician training and marketing
    • 3.2.4.5. Product improvements and innovations
    • 3.2.4.6. Mergers, acquisitions, and partnerships
    • 3.2.4.7. Product portfolio management
• 3.3. Transcatheter Heart Valve Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Transcatheter Heart Valve Market: Application Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Application Market Share Analysis, 2024 & 2033
• 4.3. Segment Dashboard
• 4.4. Transcatheter Aortic Valve
  • 4.4.1. Transcatheter aortic valve market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Transcatheter Pulmonary Valve
  • 4.5.1. Transcatheter pulmonary valve market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Transcatheter Mitral Valve
  • 4.6.1. Transcatheter mitral valve market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Transcatheter Heart Valve Market: Technology Estimates & Trend Analysis

• 5.1. Definition and Scope
• 5.2. Application Market Share Analysis, 2024 & 2033
• 5.3. Segment Dashboard
• 5.4. Balloon Expanded Transcatheter Valve
  • 5.4.1. Balloon expanded transcatheter valve market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Self-Expanded Transcatheter Valve
  • 5.5.1. Self-expanded transcatheter valve market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Transcatheter Heart Valve Market: Regional Estimates & Trend Analysis by Application and Technology

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. Key company market share analysis, 2024
  • 7.2.2. Medtronic
    • 7.2.2.1. Overview
    • 7.2.2.2. Financial Performance
    • 7.2.2.3. Product Benchmarking
    • 7.2.2.4. Strategic Initiatives
  • 7.2.3. Abbott
    • 7.2.3.1. Overview
    • 7.2.3.2. Financial Performance
    • 7.2.3.3. Product Benchmarking
    • 7.2.3.4. Strategic Initiatives
  • 7.2.4. Braile Biomedica
    • 7.2.4.1. Overview
    • 7.2.4.2. Financial Performance
    • 7.2.4.3. Product Benchmarking
    • 7.2.4.4. Strategic Initiatives
  • 7.2.5. Meril Life Sciences Pvt. Ltd., Inc.
    • 7.2.5.1. Overview
    • 7.2.5.2. Financial Performance
    • 7.2.5.3. Product Benchmarking
    • 7.2.5.4. Strategic Initiatives
  • 7.2.6. Edwards Lifesciences Corporation
    • 7.2.6.1. Overview
    • 7.2.6.2. Financial Performance
    • 7.2.6.3. Product Benchmarking
    • 7.2.6.4. Strategic Initiatives
  • 7.2.7. MicroPort Scientific Corporation
    • 7.2.7.1. Overview
    • 7.2.7.2. Financial Performance
    • 7.2.7.3. Product Benchmarking
    • 7.2.7.4. Strategic Initiatives
  • 7.2.8. Venus Medtech (Hangzhou) Inc.
    • 7.2.8.1. Overview
    • 7.2.8.2. Financial Performance
    • 7.2.8.3. Product Benchmarking
    • 7.2.8.4. Strategic Initiatives
  • 7.2.9. JenaValve
    • 7.2.9.1. Overview
    • 7.2.9.2. Financial Performance
    • 7.2.9.3. Product Benchmarking
    • 7.2.9.4. Strategic Initiatives
  • 7.2.10. Biosensors International Group, Ltd
    • 7.2.10.1. Overview
    • 7.2.10.2. Financial Performance
    • 7.2.10.3. Product Benchmarking
    • 7.2.10.4. Strategic Initiatives
  • 7.2.11. HLT Medical (Bracco)
    • 7.2.11.1. Overview
    • 7.2.11.2. Financial Performance
    • 7.2.11.3. Product Benchmarking
    • 7.2.11.4. Strategic Initiatives

관련자료